Document is current
Any future updates will be listed below
-
Authors
da Silva, Leonard Medeiros
Rodrigues, Amanda Muniz
da Cunha, Daniel Bueno
Duarte, Vagner
Pereira, Emílio Marcelo
Koyama, Fernanda Christtanini
Ferrari, Bruno Lemos
Dienstmann, Rodrigo https://orcid.org/0000-0001-5997-318X
-
Funding
Funding for this research was provided by:
Daiichi Sankyo Brazil
- License Information
-
More Information
Article History
Received: 7 March 2025
Revised: 4 June 2025
Accepted: 4 July 2025
First Online: 26 July 2025
Declarations
:
: The project was approved by the Institutional Ethics Committee with the number CAAE 66655722.7.0000.0227. We obtained a waiver of patient consent.
: Rodrigo Dienstmann declares an advisory role for Roche, Foundation Medicine, AstraZeneca, and Pfizer; received a speaker’s fee from Roche, Foundation Medicine, GuardantHealth, Ipsen, Amgen, Servier, Sanofi, Libbs, Merck Sharp & Dohme, Lilly, AstraZeneca, Johnson and Johnson, Takeda, Bristol Myers Squibb, GlaxoSmithKline, Gilead, Pfizer, research grants from Merck, Novartis, Daiichi-Sankyo, GlaxoSmithKline, Pfizer, and AstraZeneca; and is an investor in Trialing Health, S.L. Leonard Medeiros da Silva received a speaker’s fee from AstraZeneca and Takeda. The other authors do not have conflicts of interest to declare.
